PE20200800A1 - Composiciones que comprenden derivados de trifenilfosfonio como anticancerigenos - Google Patents
Composiciones que comprenden derivados de trifenilfosfonio como anticancerigenosInfo
- Publication number
- PE20200800A1 PE20200800A1 PE2020000569A PE2020000569A PE20200800A1 PE 20200800 A1 PE20200800 A1 PE 20200800A1 PE 2020000569 A PE2020000569 A PE 2020000569A PE 2020000569 A PE2020000569 A PE 2020000569A PE 20200800 A1 PE20200800 A1 PE 20200800A1
- Authority
- PE
- Peru
- Prior art keywords
- tpp
- derivative
- pharmaceutical composition
- naphthylmethyl
- triplenylphosphonium
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/28—Phosphorus compounds with one or more P—C bonds
- C07F9/50—Organo-phosphines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oncology (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Emergency Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
La presente invencion se refiere a una composicion farmaceutica caracterizada porque comprende un compuesto derivado de tri-fenil-fosfonio (TPP) tal como 2-buteno-1,4-bis-TPP o derivado, 2-clorobencil-TPP o derivado, 3-metilbencil-TPP o derivado, 2,4-diclorobencil-TPP o derivado, 1-naftilmetil-TPP o derivado, 1-naftilmetil-TPP o derivado, y p-xililenbis-TPP o derivado. Adicionalmente, la composicion farmaceutica comprende un agente terapeutico que tiene un efecto anti-mitocondrial, tal como un antibiotico, inhibidor de la biogenesis mitocondrial, mitorriboscina, mitoquetoscina, entre otros. Los compuestos derivados de TPP presentes en la composicion farmaceutica, fijan como objetivos las mitocondrias en celulas madre cancerosas (CSCs), siendo utiles en el tratamiento y/o prevencion de la recurrencia de tumores, metastasis, resistencia a farmacos y/o resistencia a radioterapia, asi como tambien para terapias anticancerosas, minimizando o evitando efectos secundarios distintos a los deseados en celulas normales.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762590432P | 2017-11-24 | 2017-11-24 | |
| PCT/US2018/062174 WO2019104115A1 (en) | 2017-11-24 | 2018-11-21 | Triphenylphosphonium-derivative compounds for eradicating cancer stem cells |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20200800A1 true PE20200800A1 (es) | 2020-08-10 |
Family
ID=66632164
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2020000569A PE20200800A1 (es) | 2017-11-24 | 2018-11-21 | Composiciones que comprenden derivados de trifenilfosfonio como anticancerigenos |
Country Status (20)
| Country | Link |
|---|---|
| US (2) | US10980821B2 (es) |
| EP (1) | EP3713559B1 (es) |
| JP (1) | JP7066847B2 (es) |
| KR (1) | KR102227834B1 (es) |
| CN (1) | CN111971040B (es) |
| AU (2) | AU2018373053C1 (es) |
| BR (1) | BR112020010313A2 (es) |
| CA (1) | CA3083023A1 (es) |
| CL (1) | CL2020001355A1 (es) |
| CO (1) | CO2020006472A2 (es) |
| CR (1) | CR20200238A (es) |
| EC (1) | ECSP20032315A (es) |
| IL (1) | IL274794B (es) |
| MX (1) | MX2020005311A (es) |
| PE (1) | PE20200800A1 (es) |
| PH (1) | PH12020550685A1 (es) |
| RU (1) | RU2020120686A (es) |
| SG (1) | SG11202004729QA (es) |
| WO (1) | WO2019104115A1 (es) |
| ZA (1) | ZA202102179B (es) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3060510A1 (en) | 2017-04-21 | 2018-10-25 | Lunella Biotech, Inc. | Vitamin c and doxycycline: a synthetic lethal combination therapy for eradicating cancer stem cells (cscs) |
| US11229657B2 (en) | 2017-04-21 | 2022-01-25 | Lunella Biotech, Inc. | Targeting hypoxic cancer stem cells (CSCs) with doxycycline: implications for improving anti-angiogenic therapy |
| US12006553B2 (en) | 2017-05-19 | 2024-06-11 | Lunella Biotech, Inc. | Companion diagnostics for mitochondrial inhibitors |
| RU2019142102A (ru) | 2017-05-19 | 2021-06-21 | Лунелла Байотек, Инк. | Антимитосцины: направленные ингибиторы митохондриального биогенеза для эрадикации злокачественных стволовых клеток |
| WO2019075219A1 (en) | 2017-10-11 | 2019-04-18 | Lunella Biotech, Inc. | ANTIMITOCHONDRIAL INHIBITORS FOR ONCOGENES RAS AND MYC |
| CR20200238A (es) * | 2017-11-24 | 2020-12-04 | Lunella Biotech Inc | Compuestos derivados de trifenilfosfonio para erradicar células madre cancerosas |
| US11497759B2 (en) | 2017-12-01 | 2022-11-15 | Lunella Biotech, Inc. | Repurposcins: targeted inhibitors of mitochondrial biogenesis for eradicating cancer stem cells |
| US12188936B2 (en) | 2018-06-01 | 2025-01-07 | Lunella Biotech, Inc. | Biomarkers and therapeutics for endocrine therapy resistance |
| KR20210072026A (ko) | 2018-10-02 | 2021-06-16 | 루넬라 바이오테크 인코포레이티드 | 세놀리틱 약물로서 아지트로마이신 및 록시스로마이신 유도체 |
| WO2020214754A1 (en) | 2019-04-16 | 2020-10-22 | Lunella Biotech, Inc. | Alkyl-tpp compounds for mitochondria targeting and anti-cancer treatments |
| EP3976197B1 (en) | 2019-05-24 | 2025-07-16 | Lunella Biotech, Inc. | Therapeutics and methods for predicting and overcoming endocrine resistance in breast cancer |
| US20220249438A1 (en) * | 2019-06-26 | 2022-08-11 | Lunella Biotech, Inc. | Carbocyanine compounds for targeting mitochondria and eradicating cancer stem cells |
| WO2021024208A1 (en) * | 2019-08-06 | 2021-02-11 | Lunella Biotech, Inc. | Tpp-derivatives for mitochondria-targeted cancer therapies |
| EP4048246B1 (en) * | 2019-10-24 | 2024-07-10 | The Medical College of Wisconsin, Inc. | Mitochondria-targeted atovaquone: a more potent and more effective antitumor, antimicrobial, and antimalarial drug |
| EP4139484A4 (en) | 2020-04-24 | 2024-08-28 | Lunella Biotech, Inc. | THERAPEUTIC METHODS FOR THE PREVENTION OF TUMOR METASTASES AND RECURRENCES |
| CN115433228B (zh) * | 2022-09-13 | 2024-10-15 | 宁波市第一医院 | 一种线粒体靶向的卡瓦胡椒素a衍生物及其合成方法和应用 |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE1046046B (de) * | 1956-06-29 | 1958-12-11 | Basf Ag | Verfahren zur Herstellung von quartaeren Phosphoniumhalogeniden |
| US3662065A (en) * | 1970-02-09 | 1972-05-09 | Monsanto Co | Chloro substituted benzyl triphenyl phosphonium halides as anthelmintics |
| US4187300A (en) * | 1978-12-20 | 1980-02-05 | The United States Of America As Represented By The Secretary Of The Army | Use of phosphonium salts in treatment of African trypanosomiasis |
| WO2005019233A1 (en) | 2003-08-22 | 2005-03-03 | Antipodean Pharmaceuticals, Inc. | Mitoquinone derivatives used as mitochondrially targeted antioxidants |
| RU2318500C2 (ru) * | 2005-10-18 | 2008-03-10 | Общество С Ограниченной Ответственностью "Митотехнология" | Способ воздействия на организм путем адресной доставки биологически активных веществ в митохондрии, фармацевтическая композиция для его осуществления и соединение, применяемое для этой цели |
| WO2008119688A1 (en) * | 2007-04-03 | 2008-10-09 | Basf Se | Photoactivable nitrogen bases |
| DE102007025423A1 (de) | 2007-05-30 | 2008-12-04 | Friedrich-Schiller-Universität Jena | Triphenylphosphonium-Derivate zum gezielten Transport und Freisetzen von Substanzen in Mitochondrien sowie Verfahren zu deren Verwendung |
| WO2013019975A1 (en) | 2011-08-03 | 2013-02-07 | University Of Iowa Research Foundation | Compositions and methods of treating cancer |
| WO2014124384A1 (en) * | 2013-02-08 | 2014-08-14 | University Of Iowa Research Foundation | Compositions and methods for cancer therapy |
| UA116469C2 (uk) | 2013-04-24 | 2018-03-26 | Смарт Брейн С.Р.О. | Похідні тамоксифену для лікування новоутворень, особливо з високим рівнем білка her2 |
| US20170189429A1 (en) * | 2014-07-10 | 2017-07-06 | Rhode Island Hospital | Treating Arrhythmia with Mitochondrial-Targeted Antioxidants |
| CZ307146B6 (cs) * | 2015-03-31 | 2018-02-07 | Kkcg Se | Trifenylfosfoniové analogy biguanidu, způsob jejich přípravy a jejich použití jako léčiva |
| PL229277B1 (pl) | 2015-07-28 | 2018-06-29 | Centrum Badan Molekularnych I Makromolekularnych Polskiej Akademii Nauk | Zastosowanie medyczne soli trifenylofosfoniowych |
| CN105325454B (zh) * | 2015-11-20 | 2017-06-06 | 华南农业大学 | 新型复合季鏻盐及其制备方法与抗菌应用 |
| CR20200238A (es) * | 2017-11-24 | 2020-12-04 | Lunella Biotech Inc | Compuestos derivados de trifenilfosfonio para erradicar células madre cancerosas |
| KR20210072026A (ko) * | 2018-10-02 | 2021-06-16 | 루넬라 바이오테크 인코포레이티드 | 세놀리틱 약물로서 아지트로마이신 및 록시스로마이신 유도체 |
-
2018
- 2018-11-21 CR CR20200238A patent/CR20200238A/es unknown
- 2018-11-21 CN CN201880084974.9A patent/CN111971040B/zh active Active
- 2018-11-21 JP JP2020528317A patent/JP7066847B2/ja active Active
- 2018-11-21 EP EP18880479.3A patent/EP3713559B1/en active Active
- 2018-11-21 WO PCT/US2018/062174 patent/WO2019104115A1/en not_active Ceased
- 2018-11-21 KR KR1020207017888A patent/KR102227834B1/ko active Active
- 2018-11-21 CA CA3083023A patent/CA3083023A1/en active Pending
- 2018-11-21 BR BR112020010313-6A patent/BR112020010313A2/pt not_active Application Discontinuation
- 2018-11-21 AU AU2018373053A patent/AU2018373053C1/en active Active
- 2018-11-21 PE PE2020000569A patent/PE20200800A1/es unknown
- 2018-11-21 RU RU2020120686A patent/RU2020120686A/ru unknown
- 2018-11-21 SG SG11202004729QA patent/SG11202004729QA/en unknown
- 2018-11-21 US US16/766,472 patent/US10980821B2/en active Active
- 2018-11-21 MX MX2020005311A patent/MX2020005311A/es unknown
-
2020
- 2020-05-20 IL IL274794A patent/IL274794B/en active IP Right Grant
- 2020-05-22 CL CL2020001355A patent/CL2020001355A1/es unknown
- 2020-05-22 PH PH12020550685A patent/PH12020550685A1/en unknown
- 2020-06-15 EC ECSENADI202032315A patent/ECSP20032315A/es unknown
- 2020-06-23 CO CONC2020/0006472A patent/CO2020006472A2/es unknown
-
2021
- 2021-03-11 US US17/199,087 patent/US11738034B2/en active Active
- 2021-03-31 ZA ZA2021/02179A patent/ZA202102179B/en unknown
- 2021-04-07 AU AU2021202123A patent/AU2021202123B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20200800A1 (es) | Composiciones que comprenden derivados de trifenilfosfonio como anticancerigenos | |
| CL2023000846A1 (es) | Terapia de combinación que incluye inhibidor de krasg12c y agente farmacéuticamente activo para tratar cáncer | |
| CL2023002383A1 (es) | Compuesto de quinazolina para inducir la degradación de la proteína kras mutante g12d | |
| DOP2019000294A (es) | Antimitoscinas: inhibidores específicos de la biogénesis mitocondrial para erradicar células madre cancerosas | |
| CO2019008487A2 (es) | Compuesto de quinazolina | |
| PE20180394A1 (es) | Composiciones que comprenden una combinacion de un anticuerpo anti muerte programada 1 (pd-1) y otro anticuerpo | |
| CO2021008895A2 (es) | Derivados de 2-oxoquinazolina como inhibidores de metionina adenosiltransferasa 2a | |
| MX2016008201A (es) | Tratamiento del cancer usando combinaciones de inhibidores de erk y raf. | |
| ECSP20033467A (es) | Compuestos macrocíclicos para tratar enfermedades | |
| CL2019000821A1 (es) | Composiciones, métodos y usos para inhibir la actividad arginasa. (divisional solicitud 201801134) | |
| CO2018009132A2 (es) | Composiciones farmacéuticas y métodos para contrarrestar la cardiotoxicidad inducida por quimioterapia | |
| BR112020017090A8 (pt) | Imunoterapias relacionadas com microbioma | |
| MX2020001550A (es) | Terapia de combinacion que incluye un inhibidor mdm2 y uno o mas agentes farmaceuticamente activos adicionales para el tratamiento de canceres. | |
| CU20150163A7 (es) | DERIVADOS DE 5-HETEROARIL-4-FENIL-4,5-DIHIDROPIRROLO(3,4-c)PIRAZOL-6-ONA ACTIVOS COMO INHIBIDORES DE BET | |
| CL2023000921A1 (es) | Derivados de 1,2,3,4-tetrahidroquinolina como inhibidores de la activacion de yap/taz-tead | |
| BR112018008601A2 (pt) | composições compreendendo o canabidiol e segundos agentes terapêuticos para o tratamento de câncer | |
| BR112016020199A8 (pt) | composto inibidor de calicreína plasmática de humano, composição farmacêutica compreendendo o referido composto, kit e seu uso | |
| BR112015023922A2 (pt) | composição farmacêutica compreendendo um ativador de ampk e um agente serotonérgico e métodos de uso destes | |
| CO2020013968A2 (es) | Derivados de pladeniolida como agentes dirigidos a empalmosoma para tratar el cáncer | |
| MX2021015770A (es) | Inhibidores macrociclicos de mcl-1. | |
| DOP2020000100A (es) | Novedosos derivados de pirazolo-pirrolo-pirimidina como inhibidores de p2x3 | |
| CO2020013834A2 (es) | Ciertos compuestos de pladienolida y métodos de uso | |
| MX2017015532A (es) | Terapia de combinacion pac-1. | |
| UY37729A (es) | NUEVOS COMPUESTOS QUE INHIBEN LA ACTIVIDAD DE Nav1.7 | |
| BR112019008516A2 (pt) | derivado de 3,4-bipiridil pirazol, e método de preparação para o mesmo e aplicação médica do mesmo |